82611-49-2 Usage
Uses
Used in Chemical Synthesis:
D-Lysine, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-, methyl ester is used as a building block for the production of peptide or protein derivatives. The protective groups at the N2 and N6 positions allow for selective reactions at other functional groups within the molecule, enabling the synthesis of specific chemical structures.
Used in Pharmaceutical Industry:
D-Lysine, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-, methyl ester may be used as an intermediate in the synthesis of pharmaceutical compounds. The protective groups on the molecule can be selectively removed during the synthesis process, allowing for the creation of specific drug candidates with desired properties.
Used in Research and Development:
D-Lysine, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-, methyl ester can be used in research and development for studying the properties and reactivity of amino acid derivatives. The protective groups on the molecule provide a means to investigate selective reactions and the effects of these reactions on the overall structure and function of the compound.
Check Digit Verification of cas no
The CAS Registry Mumber 82611-49-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,6,1 and 1 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 82611-49:
(7*8)+(6*2)+(5*6)+(4*1)+(3*1)+(2*4)+(1*9)=122
122 % 10 = 2
So 82611-49-2 is a valid CAS Registry Number.
InChI:InChI=1/C20H30N2O6/c1-20(2,3)28-19(25)22-16(17(23)26-4)12-8-9-13-21-18(24)27-14-15-10-6-5-7-11-15/h5-7,10-11,16H,8-9,12-14H2,1-4H3,(H,21,24)(H,22,25)/t16-/m1/s1
82611-49-2Relevant academic research and scientific papers
PCSK9 ANTAGONIST COMPOUNDS
-
Page/Page column 88; 89, (2021/03/05)
Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
Concise total synthesis of aplysinellamides A and B
Gan, Haifeng,Huang, Yu,Feng, Weiyang,Zhu, Wentong,Guo, Kai
, p. 336 - 339 (2015/08/11)
Concise and efficient total syntheses of bromotyrosine-derived metabolites aplysinellamides A and B, isolated from Australian marine sponge Aplysinella sp., have been accomplished in seven steps. A condensation between cinnamic acid and Boc-D-lysine methyl ester was applied to form the amide skeleton as a key step.
